Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:SGEN's Cash-to-Debt is ranked higher than
99% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. NAS:SGEN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.76
NAS:SGEN's Equity-to-Asset is ranked higher than
64% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:SGEN: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.76 Max: 0.97
Current: 0.76
0.36
0.97
Interest Coverage No Debt
NAS:SGEN's Interest Coverage is ranked higher than
99% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:SGEN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 25.66
Beneish M-Score: -2.78
WACC vs ROIC
21.84%
-249.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -34.13
NAS:SGEN's Operating Margin % is ranked higher than
60% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. NAS:SGEN: -34.13 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SGEN' s Operating Margin % Range Over the Past 10 Years
Min: -260.49  Med: -49.69 Max: -23.35
Current: -34.13
-260.49
-23.35
Net Margin % -33.51
NAS:SGEN's Net Margin % is ranked higher than
59% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. NAS:SGEN: -33.51 )
Ranked among companies with meaningful Net Margin % only.
NAS:SGEN' s Net Margin % Range Over the Past 10 Years
Min: -242.65  Med: -48.72 Max: -23.22
Current: -33.51
-242.65
-23.22
ROE % -21.01
NAS:SGEN's ROE % is ranked higher than
63% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. NAS:SGEN: -21.01 )
Ranked among companies with meaningful ROE % only.
NAS:SGEN' s ROE % Range Over the Past 10 Years
Min: -128.57  Med: -35.29 Max: -21.01
Current: -21.01
-128.57
-21.01
ROA % -16.19
NAS:SGEN's ROA % is ranked higher than
64% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:SGEN: -16.19 )
Ranked among companies with meaningful ROA % only.
NAS:SGEN' s ROA % Range Over the Past 10 Years
Min: -50.86  Med: -18.13 Max: -12
Current: -16.19
-50.86
-12
ROC (Joel Greenblatt) % -228.23
NAS:SGEN's ROC (Joel Greenblatt) % is ranked higher than
58% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. NAS:SGEN: -228.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -903.49  Med: -405.77 Max: -178.02
Current: -228.23
-903.49
-178.02
3-Year Revenue Growth Rate 10.30
NAS:SGEN's 3-Year Revenue Growth Rate is ranked higher than
59% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. NAS:SGEN: 10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.7  Med: 35.05 Max: 148.1
Current: 10.3
7.7
148.1
3-Year EBITDA Growth Rate 25.70
NAS:SGEN's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NAS:SGEN: 25.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 2.5 Max: 25.7
Current: 25.7
-30.1
25.7
3-Year EPS without NRI Growth Rate 25.20
NAS:SGEN's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:SGEN: 25.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34  Med: -1.3 Max: 27.9
Current: 25.2
-34
27.9
GuruFocus has detected 2 Warning Signs with Seattle Genetics Inc $NAS:SGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SGEN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SGEN Guru Trades in Q1 2016

Columbia Wanger 1,763,796 sh (+8.81%)
PRIMECAP Management 13,589,187 sh (+5.49%)
Manning & Napier Advisors, Inc 289,140 sh (-19.18%)
» More
Q2 2016

SGEN Guru Trades in Q2 2016

Joel Greenblatt 30,082 sh (New)
George Soros 14,700 sh (New)
PRIMECAP Management 13,514,712 sh (-0.55%)
Columbia Wanger 1,428,393 sh (-19.02%)
Manning & Napier Advisors, Inc 228,321 sh (-21.03%)
» More
Q3 2016

SGEN Guru Trades in Q3 2016

Paul Tudor Jones 8,729 sh (New)
Manning & Napier Advisors, Inc 257,580 sh (+12.81%)
PRIMECAP Management 13,420,237 sh (-0.70%)
Columbia Wanger 682,974 sh (-52.19%)
George Soros 4,347 sh (-70.43%)
Joel Greenblatt 8,242 sh (-72.60%)
» More
Q4 2016

SGEN Guru Trades in Q4 2016

Ray Dalio 163,107 sh (New)
Jim Simons 253,313 sh (New)
Joel Greenblatt 12,900 sh (+56.52%)
Columbia Wanger 760,744 sh (+11.39%)
Paul Tudor Jones Sold Out
George Soros Sold Out
PRIMECAP Management 13,230,162 sh (-1.42%)
Manning & Napier Advisors, Inc 140,670 sh (-45.39%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:BMRN, NAS:BCRX, NAS:ANIP, NAS:BSTC, AMEX:BTX, NAS:CASC, NAS:BDSI » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc is a biotechnology company. It develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.

Seattle Genetics is a development-stage biotech focused on the development of monoclonal antibody-based therapies. The firm's lead product, Adcetris, has received approval for relapsed/refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma, and the company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Ratios

vs
industry
vs
history
PB Ratio 14.21
SGEN's PB Ratio is ranked lower than
90% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. SGEN: 14.21 )
Ranked among companies with meaningful PB Ratio only.
SGEN' s PB Ratio Range Over the Past 10 Years
Min: 1.88  Med: 9.38 Max: 35.99
Current: 14.21
1.88
35.99
PS Ratio 21.36
SGEN's PS Ratio is ranked lower than
61% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. SGEN: 21.36 )
Ranked among companies with meaningful PS Ratio only.
SGEN' s PS Ratio Range Over the Past 10 Years
Min: 9.87  Med: 18.99 Max: 45.24
Current: 21.36
9.87
45.24
Current Ratio 4.95
SGEN's Current Ratio is ranked higher than
58% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. SGEN: 4.95 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.75  Med: 4.41 Max: 31.28
Current: 4.95
2.75
31.28
Quick Ratio 4.49
SGEN's Quick Ratio is ranked higher than
56% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SGEN: 4.49 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.75  Med: 4.28 Max: 31.28
Current: 4.49
2.75
31.28
Days Inventory 566.61
SGEN's Days Inventory is ranked lower than
97% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. SGEN: 566.61 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s Days Inventory Range Over the Past 10 Years
Min: 442.93  Med: 547.11 Max: 639.76
Current: 566.61
442.93
639.76
Days Sales Outstanding 54.06
SGEN's Days Sales Outstanding is ranked higher than
53% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. SGEN: 54.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40  Med: 61.69 Max: 562.77
Current: 54.06
40
562.77
Days Payable 250.18
SGEN's Days Payable is ranked higher than
86% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. SGEN: 250.18 )
Ranked among companies with meaningful Days Payable only.
SGEN' s Days Payable Range Over the Past 10 Years
Min: 202.64  Med: 240.81 Max: 1833.79
Current: 250.18
202.64
1833.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.90
SGEN's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SGEN: -4.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -113.5  Med: -12.05 Max: -2.2
Current: -4.9
-113.5
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 23.37
SGEN's Price-to-Net-Cash is ranked lower than
83% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. SGEN: 23.37 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGEN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.73  Med: 13.35 Max: 60.62
Current: 23.37
3.73
60.62
Price-to-Net-Current-Asset-Value 16.95
SGEN's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. SGEN: 16.95 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGEN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.58  Med: 11.12 Max: 447
Current: 16.95
3.58
447
Price-to-Tangible-Book 14.22
SGEN's Price-to-Tangible-Book is ranked lower than
86% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. SGEN: 14.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.04  Med: 9.02 Max: 21.61
Current: 14.22
2.04
21.61
Price-to-Median-PS-Value 1.12
SGEN's Price-to-Median-PS-Value is ranked lower than
58% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. SGEN: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.05 Max: 30
Current: 1.12
0.68
30
Earnings Yield (Greenblatt) % -1.70
SGEN's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. SGEN: -1.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.02  Med: 0 Max: 0
Current: -1.7
-4.02
0

More Statistics

Revenue (TTM) (Mil) $418.1
EPS (TTM) $ -1.00
Beta2.59
Short Percentage of Float16.70%
52-Week Range $32.40 - 75.36
Shares Outstanding (Mil)142.49

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 449 577 860
EPS ($) -1.55 -1.07 0.35
EPS without NRI ($) -1.55 -1.07 0.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
7 Stocks That Are Beating the Market Feb 21 2017 
Insiders Buy Herbalife, Sell MasterCard Nov 05 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 

More From Other Websites
Seattle Genetics, Inc. breached its 50 day moving average in a Bullish Manner : SGEN-US : March 23,... Mar 23 2017
Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs Mar 17 2017
Coverage initiated on Seattle Genetics by Oppenheimer Mar 16 2017
Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue? Mar 14 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics,... Mar 11 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... Mar 10 2017
Judge Blocks $2B Immunomedics-Seattle Genetics Deal (IMMU,SGEN) Mar 10 2017
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Seattle Genetics,... Mar 10 2017
March 13 Deadline Alert: Law Offices of Howard G. Smith Reminds Seattle Genetics, Inc. Investors of... Mar 10 2017
DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class... Mar 10 2017
SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events Mar 10 2017
Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted Mar 09 2017
Judge puts Seattle Genetics' $2 billion deal with Immunomedics on hold Mar 09 2017
Immunomedics Soars on Injunction Against Seattle Genetics Deal Mar 09 2017
Investor Alert: GPM Reminds Investors of the March 13 Deadline in the Class Action Lawsuit Against... Mar 09 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle... Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)